Barrington Research Reiterates “Outperform” Rating for Paysign (NASDAQ:PAYS)

Paysign (NASDAQ:PAYS)‘s stock had its “outperform” rating reaffirmed by research analysts at Barrington Research in a report issued on Wednesday,Benzinga reports. They presently have a $7.00 price target on the stock. Barrington Research’s price objective would suggest a potential upside of 225.58% from the stock’s current price.

Separately, Lake Street Capital began coverage on shares of Paysign in a research note on Friday, December 20th. They issued a “buy” rating and a $6.00 price target on the stock.

Paysign Trading Down 5.3 %

Shares of PAYS stock opened at $2.15 on Wednesday. The company has a market cap of $115.13 million, a P/E ratio of 14.33 and a beta of 0.93. The firm has a fifty day moving average price of $2.64 and a 200 day moving average price of $3.24. Paysign has a 12 month low of $2.10 and a 12 month high of $5.59.

Paysign (NASDAQ:PAYS) last announced its quarterly earnings results on Tuesday, March 25th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.02. Paysign had a return on equity of 30.64% and a net margin of 14.28%. The company had revenue of $15.61 million during the quarter, compared to the consensus estimate of $15.42 million. On average, equities analysts forecast that Paysign will post 0.21 EPS for the current year.

Insider Transactions at Paysign

In other news, insider Topline Capital Management, Ll sold 120,000 shares of the company’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $3.24, for a total value of $388,800.00. Following the completion of the sale, the insider now directly owns 5,336,146 shares of the company’s stock, valued at approximately $17,289,113.04. This represents a 2.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Mark Newcomer sold 100,000 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $2.73, for a total value of $273,000.00. Following the transaction, the chief executive officer now directly owns 8,936,886 shares in the company, valued at approximately $24,397,698.78. This represents a 1.11 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 695,900 shares of company stock worth $2,106,810. Corporate insiders own 23.40% of the company’s stock.

Institutional Trading of Paysign

Several institutional investors and hedge funds have recently added to or reduced their stakes in PAYS. PDT Partners LLC purchased a new position in shares of Paysign in the 4th quarter valued at approximately $39,000. Wells Fargo & Company MN grew its position in Paysign by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 15,385 shares of the company’s stock valued at $46,000 after buying an additional 5,243 shares during the last quarter. SG Americas Securities LLC increased its stake in Paysign by 33.5% in the 4th quarter. SG Americas Securities LLC now owns 15,508 shares of the company’s stock valued at $47,000 after buying an additional 3,895 shares during the period. Virtu Financial LLC acquired a new position in Paysign in the 4th quarter valued at $78,000. Finally, Occudo Quantitative Strategies LP raised its position in Paysign by 56.5% during the 4th quarter. Occudo Quantitative Strategies LP now owns 28,429 shares of the company’s stock worth $86,000 after buying an additional 10,268 shares during the last quarter. 25.89% of the stock is owned by hedge funds and other institutional investors.

About Paysign

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.